Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of batefenterol DPI in COPD
2015-001409-15Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of batefenterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by GSK. Primary endpoint: Weighted-mean FEV1 over 0 to 6 hours post-dose at Day 42. Started Aug 2015; status: completed.
02
Drugs
batefenterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2015-001409-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001409-15.